Hormone Antagonist
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure (NCT02997995) | UNICANCER | 2017-02-15 |
Track Hormone Antagonist automatically
Every clearance here is in the API, with alerts when new ones post.